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Background. Strategies aimed at antiretroviral therapy (ART)–free remission will target individuals with a limited viral reser-
voir. We investigated factors associated with low reservoir measured as total human immunodeficiency virus type 1 (HIV-1) DNA 
in peripheral blood mononuclear cells (PBMCs) in perinatal infection (PaHIV).
Methods. Children from 7 European centers in the Early Treated Perinatally HIV Infected Individuals: Improving Children’s 
Actual Life (EPIICAL) consortium who commenced ART aged <2 years, and remained suppressed (viral load [VL] <50 copies/mL) 
for >5 years were included. Total HIV-1 DNA was measured by quantitative polymerase chain reaction per million PBMCs. Factors 
associated with total HIV-1 DNA were analyzed using generalized additive models. Age, VL at ART initiation, and baseline CD4% 
effects were tested including smoothing splines to test nonlinear association.
Results. Forty PaHIV, 27 (67.5%) female 21 (52.5%) Black/Black African, had total HIV-1 DNA measured; median 12 (IQR, 7.3–
15.4) years after ART initiation. Eleven had total HIV-1 DNA <10 copies/106 PBMCs. HIV-1 DNA levels were positively associated 
with age and VL at ART initiation, baseline CD4%, and Western blot antibody score. Age at ART initiation presented a linear associ-
ation (coefficient = 0.10 ± 0.001, P ≤ .001), the effect of VL (coefficient = 0.35 ± 0.1, P ≤ .001) noticeable >6 logs. The effect of CD4% 
(coefficient = 0.03 ± 0.01, P = .049) was not maintained >40%.
Conclusions. In this PaHIV cohort, reduced total HIV-1 DNA levels were associated with younger age and lower VL at ART 
initiation. The impact of early-infant treatment on reservoir size persists after a decade of suppressive therapy.
Key words.  adolescents; children; early treated; HIV-1; HIV reservoir; viral suppression.
Despite the very significant gains made in the prevention of 
perinatal transmission of human immunodeficiency virus type 
1 (HIV-1), globally >150  000 infected infants are born annu-
ally. Antiretroviral therapy (ART) has revolutionized survival; 
however, alone it is unable to confer a cure, a consequence of 
an inaccessible latent pool of HIV-1–infected reservoir cells. In 
both adults and infants, initiation of ART soon after infection 
minimizes the reservoir size in resting memory CD4+ T cells 
and limits the evolution of HIV-1 within reservoirs [1, 2]. In 
infants, early ART, typically defined as within 8–12 weeks of 
birth, is possible but challenging; those infected in utero can be 
identified within a few days of life, and those with intrapartum 
HIV-1 transmission by 2–6 weeks of age [3]. Rare case reports 
in perinatally infected individuals demonstrate that long-term 
viral control can be influenced by very early ART, although alone 
this is almost always insufficient for sustained viral control when 
subsequently stopped [4, 5]. Children differ immunologically 
from adults, with a more active thymus and greater capacity for 
immune regeneration, a reduced central memory T-cell com-
partment, and low immune activation state, a condition not con-
ducive for HIV-1 reservoir seeding [6, 7]. Children starting ART 
within 3 months of birth remain frequently HIV-1 seronegative 
after losing maternal antibodies and lack HIV-specific cellular 
immune responses, making them potentially more susceptible 
to uncontrolled viral replication when ART is interrupted [8, 9]. 
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Identifying factors and biomarkers, such as seronegativity, asso-
ciated with limited viral reservoir size will potentially aid iden-
tification of participants for future proof-of-concept studies 
aimed at inducing ART-free viral remission [10].
The CARMA study (Child and Adolescent Reservoir 
Measurements on Early Suppressive ART) is part of the existing 
EPIICAL consortium (Early Treated Perinatally HIV Infected 
Individuals: Improving Children’s Actual Life; www.epiical.org), 
an international collaboration whose aim is to select promising 
HIV-1 therapeutic strategies and to identify candidates among 
perinatally HIV-1–infected children and adolescents and is de-
scribed in detail previously [10].
The primary endpoint analyses of the CARMA cohort are 
presented, identifying factors that influence the establish-
ment of a low total HIV DNA level in perinatally HIV-infected 
children and adolescents on suppressive ART.
MATERIALS AND METHODS
Design
This was a multicenter, cross-sectional study enrolling subjects 
from 7 European pediatric HIV clinical research centers con-
tributing to EPIICAL, in England (3), Spain (2), and Italy (2).
Participants
Forty perinatally HIV-1–infected children who commenced 
ART within the first 24 months of life were included. Viral sup-
pression (viral load [VL] <400 copies/mL) had to be achieved 
within 12  months of ART initiation, maintained for a min-
imum of 5 years with a VL of <50 copies/mL confirmed at en-
rollment. Children with current viral hepatitis or tuberculosis 
coinfection, malignancy, pregnancy, or concomitant immu-
nosuppressive therapy were excluded. For each participant, 
data collection included demographics; age at HIV diagnosis, 
at ART start, and at time of analysis; and ART drug regimens 
ever received. Immunology (CD4 total, CD8 total, CD4% and 
CD8%, and CD4:CD8 ratio) and VL were recorded from di-
agnosis, ART initiation, throughout treatment, and at time of 
reservoir analysis. Viral load “blips” (defined as a rise in plasma 
VL from 50 to 399 copies/mL returning to <50 copies/mL on 
repeat sampling) and single annual viral “spikes” (defined as VL 
400–999 copies/mL returning to <50 copies/mL on repeat sam-
pling) were permitted.
Laboratory Analyses
Total HIV-1 DNA
Total HIV-1 DNA was measured in purified peripheral blood 
mononuclear cells (PBMCs) by real-time quantitative poly-
merase chain reaction (qPCR). Total nucleic acids were ex-
tracted from PBMCs on the QIAsymphony platform using 
the DSP Virus/Pathogen Mini Kit (Qiagen) according to the 
manufacturer’s protocol. Primers were designed for HIV-1 
long terminal repeat and the genomic reference gene pyruvate 
dehydrogenase as previously described [11]. Quantification of 
cell-associated HIV-1 DNA by qPCR was determined using 
20 μL of extract and a standard curve with known copy numbers 
in 10-fold dilutions. The limit of quantitation is 10 copies/106 
PBMCs and the limit of detection is 1 copy/106 PBMCs. Assays 
were performed in triplicate.
Fourth-Generation Antibody/Antigen
Serological status was assessed by plasma venous sampling 
using the fourth-generation Abbott ARCHITECT HIV Ag/Ab 
Combo assay.
Western Blot: HIV-Specific Antibody Characterization
Plasma samples were tested as previously described [12]. 
Human immunodeficiency virus Western blot (WB) kit 2.2 
(Medical Systems, Genova, Italy) was used, following the 
manufacturer’s instructions, to detect specific antibody (Ab) 
responses, in 20 μL of plasma, against 10 different HIV-1 viral 
proteins (gp160, gp120, p66, p55, p51, gp41, p39, p31, p24, and 
p17) as previously described [13]. Nitrocellulose strips con-
taining HIV proteins incorporated through electrophoretic 
blotting were tested with plasma samples and with controls. 
The presence or absence of Abs to HIV was determined by 
comparing each nitrocellulose strip to the assay control strips 
tested with the nonreactive, strong reactive, and weak reactive 
controls. All of the WB strips were analyzed using the ImageJ 
software (ImageJ 1.52a; National Institutes of Health). The band 
intensity was calculated for each viral antigen in each sample, 
and compared with the intensity calculated in the strong reac-
tive control. A score of 1 was assigned when the intensity of the 
band was ≥50% of those calculated in the strong positive con-
trol for the same antigen, whereas 0.5 was assigned when the 
band intensity ranged from 10% to 49% of those found in the 
positive control. Finally, negative results (WB score = 0) were 
assigned for band intensity ranging from 0% to 9% of those 
found in the positive control. A WB score was assigned to each 
patient by adding up the number of positive and weak responses 
(from 0 to 10).
Statistical Methods
Data were displayed as a whole and summarized by HIV-1 DNA 
reservoir (groups ≤10 copies vs >10 copies/106 PBMCs). HIV-1 
DNA reservoir was dichotomized: low (≤10) vs high (>10) as 
per previous studies and reflecting the limit of assay quantita-
tion. In multivariable models, HIV-1 DNA was used as a con-
tinuous variable. In case of continuous variables, median and 
interquartile range (IQR) were assessed for nonparametric vari-
ables and mean and standard deviation for parametric variables. 
In summary tables of categorical variables, counts and per-
centages were reported and comparisons were assessed using 
Fisher exact test. For normally distributed continuous variables, 
Student t test was performed, and Mann-Whitney U test when 
nonparametric.
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To describe the association between the HIV-1 reservoir and 
the different effect of each clinical, virological, and immuno-
logical feature, a generalized additive mixed model was applied. 
Backward stepwise elimination was applied to reach the final 
multivariable model, and Akaike information criteria (AIC) 
was used to identify the best-fitting model.
To analyze possible nonlinear associations, each var-
iable was included in the model with smoothing splines. 
Smoothing parameters defining degrees of freedom (df) were 
selected according to nested AIC comparisons. ART combi-
nation at initiation was included as random intercept to cor-
rect for random variance across regimens. R software version 
3.5.2 software was used for all analyses (R Development Core 
Team, 2008).
Ethical Considerations
The CARMA study was approved by ethics committees within 
each country and informed assent/consent obtained from ado-
lescents and/or parent(s)/legal guardian in accordance with 
country-specific law. Each participant received a unique study 
number, under which data were pseudo-anonymized.
RESULTS
Forty perinatally HIV-1–infected children, 27 (67.5%) fe-
male, 21 (52.5%) Black/Black African, and 13 (32.5%) white, 
commenced ART at a median age of 4.08 (IQR, 0.25–6.23) 
months, CD4 count 1310 (IQR, 478–2376) cells/µL, CD4% 30.5 
(IQR,  19.2–42.5), and log10 VL 5.28 (IQR, 4.07–5.70) copies/
mL (Table 1). Median time to viral suppression was 4.69 (IQR, 
2.52–6.26) months. In analysis at a median of 12 (IQR, 7.3–15.4) 
years after ART initiation, median CD4 count was 872 (IQR, 
646–1053) cells/µL, CD4% 41.0 (IQR, 33.8–46.2), and total 
HIV-1 DNA <10 copies/106  PBMCs in 11 (27.5%) children. 
Of these 11 children, 5 were below the lower limit of detection 
(<1 copy/106 PBMCs), the remaining 6 children having low 
levels of detectable total HIV-1 DNA (1–9 copies/106 PBMCs). 
In the 35 children with a quantifiable total HIV-1 DNA level 
(≥1 copy/106 PBMCs), the median was 50.9 (IQR, 25.3–117.3) 
copies/106 PBMCs. Serological analyses were available for 39/40 
children. Ten children were seronegative on fourth-generation 
HIV Ab/antigen (Ag) testing at time of analysis. Five of 10 (50%) 
children with total HIV-1 DNA <10 copies/106 PBMCs and 5 
of 29 (17.2%) children with a reservoir >10 copies/106 PBMCs 
were seronegative (P = .087) (Table 1). Only 1 child with a res-
ervoir below the limit of detection (<1 copy/106 PBMCs) had 
positive HIV serology. There was a suggestive association of 
children with a reservoir of <10 copies/106 PBMCs being Ab/
Ag nonreactive compared with those with higher reservoir size 
(P = .087; Table 1).
Viral load at diagnosis was significantly lower in those with 
total HIV-1 DNA <10 copies/106 PBMCs (log10 VL, 5.70 [IQR, 
5.25–6.00] copies/mL  vs 4.66 [IQR, 4.18–5.33]  copies/mL; 
P = .030; Table 1). Children with a reservoir of <10 copies/106 
PBMCs were likely to be younger at HIV diagnosis (3.61 
[median  (IQR), 0.34–4.26] months vs 4.92 [IQR, 3.08–6.49] 
months) and at ART start (3.6 [median  (IQR), 0.10–4.49] 
months vs 4.6 [IQR, 2.66–7.64] months), although this did not 
reach statistical significance. No differences were found in pa-
tients with low vs high reservoir related to clinical stage (AIDS 
vs non-AIDS) or time to viral suppression. The median age at 
ART initiation was 4.6 (IQR, 3.11–7.04) months in those with 
positive/equivocal serology and 3.1 (IQR, 0.21–3.80) months in 
those who were seronegative (Table 1). There was no association 
of age at ART with log10 VL at ART start and serological status 
at analysis 12 years later (log10 VL, 5.3 [IQR, 4.04–5.8] copies/
mL in those with positive/equivocal serology and 5.02 [IQR, 
4.22–5.4] copies/mL in those who were seronegative).
The number of patients ever experiencing a blip and/or spike 
and time from viral suppression to first blip and/or spike were 
comparable between groups (Table 1). Immunological param-
eters (total/% CD4, CD8, and CD4:CD8) did not differ be-
tween groups at diagnosis, ART initiation, viral suppression, or 
12 years later at time of reservoir analysis.
Only age and VL at ART initiation and baseline CD4% were 
selected to be included in the multivariable model to predict 
reservoir size. Total HIV-1 DNA levels were positively asso-
ciated with age and VL at ART initiation and baseline CD4% 
(Figure 1). While age at ART initiation presented a linear asso-
ciation (coefficient = 0.10 ± 0.001, P ≤ .001, df = 2), the effect 
of VL (coefficient = 0.35 ± 0.10, P ≤ .001, df = 3) only was no-
ticeable for individuals with VLs at ART initiation above 6 logs. 
The effect of baseline CD4% (coefficient = 0.03 ± 0.01, P = .049) 
was not maintained above 40%. Western blot score was signif-
icantly positively associated with HIV DNA reservoir adjusted 
for age and considering drug combinations as random inter-
cepts (P < .001; Figure 1).
DISCUSSION
Of 40 HIV-1 perinatally infected children from 7 different sites 
across 3 European countries initiating ART in infancy (median 
age, 4  months), with viral suppression maintained for more 
than a decade, just over one-quarter had very low/undetect-
able total HIV-1 DNA levels (<10 copies/106 PBMCs). Patients 
with a lower reservoir size commenced ART earlier after birth 
and at a lower baseline VL. The association of earlier ART in-
itiation following primary infection and a reduced reservoir 
size is well-established in adults and is increasingly recog-
nized for children, further supported by this study. The impact 
of pretreatment VL on future reservoir size is less established. 
Baseline VL is associated with time to viral suppression, and 
subsequent risk of viral rebound in adult populations and with 
persistent residual low-level viremia on ultrasensitive assays 
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Table 1. Immunological and Virological Parameters Compared by Reservoir Size
Parameter All (N = 40) >10 Copies/106 PBMCs (n = 29) <10 Copies/106 PBMCs (n = 11) P Value
Region, No. (%)    .062
 Italy 16 (40.0) 9 (31.0) 7 (63.6)  
 Spain 5 (12.5) 3 (10.3) 2 (18.2)  
 United Kingdom 19 (47.5) 17 (58.6) 2 (18.2)  
Sex, female, No. (%) 27 (67.5) 17 (58.6) 10 (90.9) .068
Race/ethnicity, No. (%)    .663
 White 13 (32.5) 8 (27.6) 5 (45.5)  
 Black/Black African 21 (52.5) 16 (55.15) 5 (45.5)  
 Other 6 (15.0) 5 (17.25) 1 (9.09)  
Age at HIV diagnosis, mo 4.17 (2.19–6.32) 4.92 (3.08–6.49) 3.61 (0.34–4.26) .084
AIDS diagnosis, No. (%)    .486
 No 25 (62.5) 17 (58.6) 8 (72.7)  
 Yes 15 (37.5) 12 (41.4) 3 (27.3)  
Age at ART start, mo 4.08 (0.25–6.23) 4.59 (2.66–7.64) 3.61 (0.10–4.49) .071
Follow-up, y 13.0 (8.19–16.1) 13.6 (8.29–16.4) 10.7 (8.99–15.0) .892
Virology     
 VL at diagnosis, log copies/mL 5.60 (4.98–5.93) 5.70 (5.25–6.00) 4.66 (4.18–5.33) .030
 VL at ART start, log copies/mL 5.28 (4.07–5.70) 5.48 (4.91–5.80) 4.64 (4.00–5.18) .119
 Time to viral suppression, mo 4.69 (2.52–6.26) 4.59 (3.21–6.46) 4.79 (1.93–5.11) .844
 VL blip. No. (%) 11 (27.5) 10 (34.5) 1 (9.09) .233
 Time to blip, y 3.7 (2.35–7.26) 3.31 (2.23–7.30) 6.48 (6.48–6.48) .723
 Viral spike, No. (%) 5 (12.5) 3 (10.3) 2 (18.2) .603
 Time to spike, y 1.53 (0.86–3.53) 3.52 (2.53–7.97) 0.61 (0.48–0.73) .200
Immunology     
 At diagnosis     
  CD4 count 1515 (637–2235) 1510 (643–2120) 1621 (827–2955) .721
  CD4 % 31.0 (18.0–38.0) 34.0 (18.0–38.0) 30.5 (25.2–39.0) 1.000
  CD8 count 1406 (720–2170) 985 (639–1931) 2170 (2115–3226) .077
  CD8 % 32.0 (25.0–40.0) 29.0 (22.5–40.0) 35.0 (33.0–47.0) .157
 At ART start     
  CD4 count 1310 (478–2376) 948 (478–2284) 1506 (988–2965) .590
  CD4 % 30.5 (19.2–42.5) 27.0 (19.0–41.0) 33.0 (30.0–45.0) .482
  CD8 count 1068 (795–2129) 960 (695–1688) 2115 (1380–2170) .166
  CD8 % 31.0 (26.5–40.0) 30.0 (25.0–40.0) 34.0 (30.8–36.5) .500
  CD4/CD8 0.84 (0.60–1.57) 0.82 (0.59–1.98) 0.89 (0.64–0.94) .749
 At viral suppression   
  CD4 count 1710 (924–2263) 1680 (891–2120) 2028 (1535–2735) .223
  CD4 % 31.0 (25.4–44.0) 30.0 (23.5–42.5) 39.5 (30.0–46.2) .161
  CD8 count 1064 (826–1732) 1064 (795–1716) 1297 (878–1715) .780
  CD8 % 27.5 (18.5–32.2) 28.0 (19.0–32.0) 24.0 (18.0–32.0) .784
 At reservoir analysis  
  CD4 count 872 (646–1053) 877 (719–1043) 630 (452–1080) .440
  CD4 % 41.0 (33.8–46.2) 41.0 (36.0–46.0) 39.0 (32.0–46.5) .606
  CD8 count 584 (402–708) 636 (434–712) 426 (292–642) .142
  CD8 % 26.0 (23.0–30.0) 26.0 (23.0–30.0) 25.0 (23.0–30.0) .761
  CD4/CD8 1.54 (1.28–1.88) 1.54 (1.31–1.88) 1.54 (1.28–2.04) .774
Serology at reservoir analysis (n = 39)  n = 29 n = 10  
 Anti-CMV IgG, No. (%)    1.000
  Negative 10 (25.6) 8 (27.6) 2 (20.0)  
  Positive 29 (74.4) 21 (72.4) 8 (80.0)  
 HIV Ag/Ab at reservoir analysis, No. (%)   .087
  Equivocal/positive 29 (74.4) 24 (82.8) 5 (50.0)  
  Nonreactive 10 (25.6) 5 (17.2) 5 (50.0)  
 Ag/Ab 4.47 (0.74–26.8) 6.02 (2.05–27.8) 1.20 (0.10–3.21) .087
 Western blot score 1.0 (0.5–2.0) 1.5 (0.5–2.0) 0.75 (0.0–1.75) .269
Data are presented as median (IQR) unless otherwise indicated.
Abbreviations: Ag/Ab, antigen/antibody; ART, antiretroviral therapy; CMV, cytomegalovirus; HIV, human immunodeficiency virus; IgG, immunoglobulin G; PBMCs, peripheral blood mononuclear cells; VL, viral load.
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[14, 15]. Perinatally HIV-1–infected infants have higher plasma 
VLs compared with older children and, despite higher CD4%, 
a longer time to viral suppression [16]. In a perinatal cohort 
from Europe and Thailand of >400 infants initiating therapy 
before 6 months of age, younger age, higher CD4%, and lower 
VL were independent predictors of viral suppression on multi-
variate analysis [17]. Starting ART even earlier, within the first 
7  days of life, is associated with more rapid viral suppression 
[18]. The rate of viral suppression following ART initiation and 
length of time on suppressive ART has been shown to be as-
sociated with a reduced reservoir size, with a recent perinatal 
European cohort demonstrating a 10% reduction in total HIV-1 
DNA for every year suppressed [11]. Reservoir size in children 
has been shown to continue to decline for more than a decade, 
but in adults appears to plateau after around 4 years of suppres-
sive therapy [13, 19].
One-quarter of participants in our cohort are HIV-1 seroneg-
ative, 12 years after initiating suppressive ART, a rate comparable 
to other early-treated perinatal cohorts [9]. Previous studies 
have reported a correlation between earlier age at ART initia-
tion and subsequent seronegativity (seropositivity odds ratio, 
13.7 [95% confidence interval, 3.1–60.2]; P = .001) ART initiated 
12–24 weeks vs <12 weeks) and with lower pretreatment VL [8, 
9], although the latter association was not supported by our data, 
possibly due to an inadequate sample size and treatment initia-
tion at a later stage (median age, 4 months) than in other cohorts 
[20, 21]. However higher Western blot score in multivariant 
analysis was strongly related to reservoir size, as reported in 
other cohorts [13, 21–23]. The close correlation found between 
the HIV-DNA and the magnitude of HIV-specific Ab response 
is consistent with the hypothesis that persistence of specific Abs 
is dependent on the HIV viral antigen exposure. Infancy repre-
sents a period of relative immunological immaturity character-
ized by the presence of maternal Abs in the infant’s blood that 
may hide the antigens. Suppression of viral replication through 
early ART in this period of life gives these children distinct HIV-
specific humoral responses, which persists over time even after 
long-term viral suppression [24]. Quantitative HIV-1–specific 
antibodies have been shown to correlate and predict plasma 
HIV-1 RNA and cell-associated DNA levels [13, 23] and may 
potentially be an adjunctive tool to screen children, particularly 
in low-income settings, using small blood volumes for future 
Figure 1. Generalized additive mixed multivariable model plots showing the association between the age at antiretroviral therapy (ART) (A), human immu-
nodeficiency virus (HIV) RNA viral load (VL) at ART initiation (B), baseline % CD4 (C), and Western blot (WB) score (D) and the HIV reservoir size (HIV copies 
per million peripheral blood mononuclear cells [PBMCs]). ART combinations at initiation were included as random intercepts. The shaded areas indicate the 
95% confidence intervals. Smooth terms are specified showing the effective degrees of freedom (Edf) for each of the variables included in the model. While 
age at ART initiation and WB score presented a linear association, the effect of VL was only noticeable for individuals with VLs at ART initiation above 6 logs. 
The effect of baseline CD4% was not maintained above 40%.
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intervention studies aimed at ART-free remission [23]. It re-
mains unclear as to whether seronegativity will confer advantage 
in future treatment interruption studies in children, or poten-
tially increase susceptibility to uncontrolled viral replication.
Our study has several limitations, being a cross-sectional 
analysis of reservoir dynamics in children and adolescents com-
mencing ART a decade ago with limited numbers reducing ana-
lytical power. However, this reflects the clinical reality; very small 
numbers of children who start ART in infancy achieve and con-
sistently maintain viral control for many years. For this reason, 
the study entry criteria were broad: ART initiation before the age 
of 2 years with viral suppression for at least 5 years. Yet of >400 
children aged 7–18 years in pediatric care in 7 European cen-
ters, <1 in 10 fulfilled the criteria. The multicenter, multicountry 
enrollment, the length of sustained viral suppression, and pre-
treatment VL data frequently absent in perinatal cohorts adds 
weight to our data. Although quantification of total HIV-1 DNA 
overestimates the size of the reservoir, lack of universal stand-
ards make between-study comparisons complex, particularly 
as many data sets are single-cohort studies. Subsequent immu-
nological and virological secondary endpoint analyses in the 
CARMA cohort are ongoing; cell-associated HIV-1 RNA and 
DNA, near full-length single-genome sequencing to infer on 
intact provirus, and the association of natural killer cell func-
tion with HIV-1 DNA and T-cell markers are to be presented 
at the Conference on Retroviruses and Opportunistic Infections 
2020 (www.croiconference.org/abstracts/search-abstracts/). 
Following this initial cross-sectional analysis, the CARMA parti-
cipants are being offered enrollment in a longitudinal follow-on 
study, looking at changing reservoir dynamics as they enter early 
adult life. Additional cohorts of early-treated children on sus-
tained suppressive ART from South Africa and Thailand are 
being invited to join the CARMA cohort to explore potential 
differences in high-prevalence settings.
Despite variations between studies, time to ART start, pre-
treatment VL, and length of viral suppression remain consistent 
markers associated with the likelihood of a smaller reservoir 
size. Children and adolescents who started ART in the first 
months of life, with a lower VL and who have remained sup-
pressed, may be preferred candidates for future intervention 
studies aiming for ART-free remission.
CONCLUSIONS
One-quarter of early-treated, perinatally infected children have 
low reservoir 12 years after enrollment. Initiation of ART at a 
younger age and lower plasma VL were associated with a lower 
HIV-1 viral reservoir in PBMCs a decade later in the context of 
sustained virological suppression. While the clinical benefits of 
early-infant ART are profound, whether a smaller latent reser-
voir can confer future ART-free advantage remains an elusive 
question for a population that currently faces a lifetime on ART.
Supplementary Data
Supplementary materials are available at Journal of the Pediatric Infectious 
Diseases Society online.
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